Remove

U.S. Patent a Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10623410
Filing Date		2003-07-18
First Named Inventor	Carr	et al.
Art Unit		3671
Examiner Name	Rayn	mond W. Addie
Attorney Docket Numb	or	0112905.023

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines whe Relevant Passages or Rele Figures Appear			
	1	3801421		1974-04	4-02	Allen et al.					
	2	4336286		1982-06	6-22	Tomarin et al.					
	3	5058335		1991-10	0-22	Richter et al.					
If you wis	h to a	dd additional U.S. Pater							Add		
			U.S.P	ATENT.	APPLI	CATION PUB	LICATIONS		Remove	1	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant of cited Document		Relev	,Columns ant Passa	ges or F	
						or disco book		Figure	s Appear		
	1					or discussion		Figure	s Appear		
If you wis	_	d additional U.S. Publi	shed Ap	plication	n citatio		olease click the Ad]	
If you wis	_	id additional U.S. Publis		<u> </u>							
If you wis Examiner Initial*	h to a	dd additional U.S. Public Foreign Document Number ³		FOREK		n information prent DOCUM		d buttor	n. Add	elumns,lievant	TS

U.S.PATENTS

	2	woo	220903	wo		2002-03-14	Prevost			
If you wish to add additional Foreign Patent Document citation information please click the Add button Add										
NON-PATENT LITERATURE DOCUMENTS Remove										
	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, cotalog, etc), date, pages(e), volume-issue number(e), publisher, city and/or country where published.							Ţs		
	1 International Search Report for International Patient Application No. PCT/US0143524 that corresponds to the present application and of which the references cited above was cited therein.									
If you wish to add additional non-patent literature document citation information please click the Add button Add										
	EXAMINER SIGNATURE									
Exami	Examiner Signature Date Considered									

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See for Code of USPTO Platent Documents at year, LISPTO,000 or MPEP 901.04. * Enter office and assued the document, by the to-elect code (VIPO Standard ST3,). * Explanese parted convenient, the notication of the parent for seing roll the Engerer mater procedure the senior inches for paperts document. * (*Incl of Cocument by the appropriate symbols as indicated on the document under WIPO Standard ST,168 (possible. * Applicant is to place a check mark here fittingle language amentation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10623410		
Filing Date		2003-07-18		
First Named Inventor	Carr	et al.		
Art Unit		3671		
Examiner Name	Raym	Raymond W. Addie		
Attorney Docket Numb	er .	0112905-023		

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication of from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information sideosure statement. See 37 CFR 137(a)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.57(c) for the control of the control

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Robert W. Connors/	Date (YYYY-MM-DD)	2006-05-17
Name/Print	Robert W. Connors	Registration Number	46639

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to life (and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12 Card 37 CFR.

1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. 0. Bot 1450, Alexandria, V.3.251.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. 0. Box 1450, Alexandria, V.3.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.